PMID- 20167630
OWN - NLM
STAT- MEDLINE
DCOM- 20100816
LR  - 20131121
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 19
IP  - 5
DP  - 2010 Apr
TI  - Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not 
      renal disease in the MRL/lpr mouse model of systemic lupus.
PG  - 599-612
LID - 10.1177/0961203309355299 [doi]
AB  - Intravenous immunoglobulin (IVIG) has a therapeutic potential in many autoimmune 
      diseases. Based on its immune modulating and complement inhibiting effects, IVIG 
      has been tested in systemic lupus erythematosus (SLE), but due to osmotic tubular 
      injury caused by immunoglobulin-stabilizing sugar components, lupus nephritis had 
      been accelerated in some patients, thus IVIG use in SLE has been abandoned. The 
      availability of non-sugar-stabilized IVIG raised the possible re-evaluation of 
      IVIG for SLE. We investigated high-dose, long-term non-sugar-stabilized IVIG 
      treatment on skin and renal SLE manifestations in the MRL/lpr mouse model. 
      Animals were treated once a week with glycine-stabilized IVIG or saline (0.2 ml/ 
      10 g BW) from 6 weeks until they were humanely killed at 5 months of age. IVIG 
      diminished macroscopic cutaneous lupus compared with saline treated mice. 
      Histology and complement-3 immunostaining also demonstrated a significant 
      reduction of skin disease after IVIG treatment. However, renal histology and 
      function were similar in both groups. Compared with typical osmotic tubular 
      damage induced by 5% sucrose and 10% maltose (used for IVIG stabilization), we 
      did not observe any osmotic tubular injury in the glycine-stabilized IVIG treated 
      mice. Our data demonstrate a beneficial effect of IVIG on skin lupus without 
      renal side-effects. Deeper understanding of the organ-specific pathomechanism may 
      aid an individualized SLE therapy.
FAU - Racz, Z
AU  - Racz Z
AD  - Institute of Pathophysiology, Semmelweis Medical University, Nagyvarad ter 4., 
      Budapest 1089, Hungary.
FAU - Nagy, E
AU  - Nagy E
FAU - Rosivall, L
AU  - Rosivall L
FAU - Szebeni, J
AU  - Szebeni J
FAU - Hamar, P
AU  - Hamar P
LA  - eng
GR  - Arthritis Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100218
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Immunoglobulins, Intravenous)
RN  - TE7660XO1C (Glycine)
SB  - IM
EIN - Lupus. 2012 May;21(6):688
MH  - Animals
MH  - *Disease Models, Animal
MH  - Glycine
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Kidney Diseases/*etiology/pathology
MH  - Lupus Erythematosus, Systemic/*complications
MH  - Mice
MH  - Mice, Inbred MRL lpr
MH  - Skin Diseases/*etiology/*prevention & control
EDAT- 2010/02/20 06:00
MHDA- 2010/08/17 06:00
CRDT- 2010/02/20 06:00
PHST- 2010/02/20 06:00 [entrez]
PHST- 2010/02/20 06:00 [pubmed]
PHST- 2010/08/17 06:00 [medline]
AID - 0961203309355299 [pii]
AID - 10.1177/0961203309355299 [doi]
PST - ppublish
SO  - Lupus. 2010 Apr;19(5):599-612. doi: 10.1177/0961203309355299. Epub 2010 Feb 18.